Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the r...
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
G1's product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S.
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is ...
